期刊文献+

辅助化疗方案对乳腺癌妇女认知功能的影响

下载PDF
导出
摘要 目的明确两种常用辅助化疗方案对Ⅱ/Ⅲ期雌激素受体/孕激素受体(ER/PR)阴性绝经后乳腺癌妇女认知功能影响。方法随机单中心入组Ⅱ/Ⅲ期ER/PR阴性绝经后乳腺癌妇女,随机接受ATC方案(给予多柔比星、紫杉醇及环磷酰胺)或TC方案(给予多西紫杉醇及卡铂)化疗,在术后10~14d及术后12个月,用霍普金斯词;12学习测验中文修订版(HVLT.R)评估患者学习记忆能力,采用连线测验(TMT)评估患者处理速度及执行能力。结果两组间化疗前HVLT-R中文版评分及TMT评分差异无统计学意义,ATC方案术后12个月HVLT—R总回忆正确率23%,延迟回忆正确率7%,延迟再认数3%。TC方案分别为51%,21%,11%(P〈O.05)。ATC方案术后12个月TMT—A为(74.3±11.1)s,TMT.B为(202.1±65.3)S,(TMT—B).(TMT—A)为(127.8±12.1)S,TC组分别为(50.3±12.8),(134.3±44.3),(94.0±8.5)s,总耗时数较Tc方案长(P〈0.05)。结论ATC方案较Tc方案更显著影响豫东地区激素受体阴性Ⅱ/Ⅲ期绝经后乳腺癌患者学习记忆能力、处理速度及执行能力。
出处 《医药导报》 CAS 北大核心 2013年第10期1323-1325,共3页 Herald of Medicine
  • 相关文献

参考文献7

  • 1QUESNEL C,SAVARD J,IVERS H.Cognitive impairments associated with breast cancer treatments:Results from a longitudinal study[J].Breast Cancer Res Treat,2009,16(1):113-123.
  • 2AZIM H A,DE AZAMBUJA E,COLOZZA M,et al.Long-term toxic effects of adjuvant chemotherapy in breast cancer[J].Ann Oncol,2011,22(9):1939-1947.
  • 3CHEUNG Y T,CHUI W K,CHAN A.Neuro-cognitive impa-irment in breast cancer patients:Pharmacological considerations[J].Crit Rev Oncol Hematol,2012,83(1):99-111.
  • 4石川,于欣,吴尊友,Robert K.Heaton,JIN Hua,Thomas D.Marcotte,Joseph Sadek,Igor Grant.中国HIV+/AIDS患者神经心理学初步研究[J].中国心理卫生杂志,2005,19(5):343-346. 被引量:29
  • 5MOSES J A Jr.Test review-comprehensive trail making test(CTMT) [J].Arch Clin Neuropsychol,2004,19(5):703-708.
  • 6WEFEL J S,SCHAGEN S B.Chemotherapy-related cognitive dysfunction[J].Curr Neurol Neurosci Rep,2012 ,[Epub ahead of print].
  • 7CORREA D D,AHLES T A.Cognitive adverse effects of chemotherapy in breast cancer patients[J].Curr Opin Support Palliat Care,2007,1(1):57-62.

二级参考文献10

  • 1Beck AT. Beck Depression Inventory: Manual. San Antonio,TX: The Psychological Corporation, 1993.
  • 2Heaton RK, Grant I, Butters N, et al. The HNRC 500-Neuropsychology of HIV infection at different disease stages. J Int Neuropsychol Soc 1995,1(3):231-251.
  • 3AtkiusonJH, Grant I. Neuropsychiatry of human immunodeficiency virus infection. In: Berger JR & Levy RM (Edls). AIDSand the nervous system. 2nd ed. Philadelphia: Lippincott-Raven, 1997.419-449.
  • 4Rabkin JG: Prevalence of psychiatric disorders in HIV illness.Iht Rev Psychiatry 1996, 8(2-3): 157-166.
  • 5Dew MA, Ragni MV, Nimorwicz P. Infection with human immunodeficiency vims and vulnerability to psychiatry distress:A study of men with hemophilia. Arch Gen Psychiatry 1990,47(8): 737-744.
  • 6Goggin KJ, Zisook S, Heaton RK, et al. Neuropsychological performance of HIV-1 infected men with major depression. JIht Neuropsychol Soc 1997,3(5):457-464.
  • 7Hinkin CH, Van Gorp WG, Satz P, et al. Depressed mood and its relationship to neuropsychological test performance in HIV-1 seropositive individuals. J Clin Exp Neuropsychol 1992,14(12): 289-297.
  • 8China Ministry of Health and the UN Theme Group on HIV/AIDS in China. A Joint Assessment of HIV/AIDS Prevention, Treatment, and Care in China. Beijing: State Council AIDS Working Committee Office, National Center for AIDS/STD Prevention and Control, Chin CDC, UNAIDS China Office, eds. 2004.7-18.
  • 9Ellis RI, Deutsch R, Heaton RK, et al. Neurocognitive impairment is an independent risk factor for death in HIV infection.San Diego HIV Neurobehavioral Research Center Group. Arch Neurol 1997,54(4):416-424.
  • 10Heaton RK, Marcotte TD, Ellis RJ, et al. Neuropsychological profile and prognostic significance of Minor cognitive/Motor Disorder. J Neurovirol 1996,2:39.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部